您好, 歡迎來(lái)到化工儀器網(wǎng)! 登錄| 免費(fèi)注冊(cè)| 產(chǎn)品展廳| 收藏商鋪|
當(dāng)前位置:BPS Bioscience Inc.>>技術(shù)服務(wù)>>檢測(cè)相關(guān)>> BPS Bioscience的KRAS篩選和檢測(cè)服務(wù)
參 考 價(jià) | 面議 |
產(chǎn)品型號(hào)
品 牌BPS Bioscience
廠商性質(zhì)生產(chǎn)商
所 在 地
更新時(shí)間:2023-12-19 23:23:59瀏覽次數(shù):228次
聯(lián)系我時(shí),請(qǐng)告知來(lái)自 化工儀器網(wǎng)BPS Bioscience的激酶篩選和檢測(cè)服務(wù)
BPS Bioscience的代謝酶篩選和檢測(cè)服務(wù)
BPS Bioscience的KRAS篩選和檢測(cè)服務(wù)
BPS Bioscience的PCSK9篩選和檢測(cè)服務(wù)
BPS Bioscience的甲基轉(zhuǎn)移酶篩選和檢測(cè)服務(wù)
BPS Bioscience
BPS Bioscience的KRAS篩選和檢測(cè)服務(wù)
KRAS is an important protein in the RAS/MAPK signaling pathway that transmits signals from activated cell surface receptors leading to cell proliferation and survival. KRAS function is controlled by cycling through an inactive, GDP-bound state and an active, GTP-bound state. Activation of KRAS occurs when it binds to Guanine Nucleotide Exchange Factor (GEF) proteins, including SOS, which initiate the exchange of GDP for GTP. Active, GTP-bound KRAS can trigger activation of downstream signaling molecules including RAF, PI3K, and RAL. KRAS can self-inactivate by cleaving the terminal phosphate group on the GTP, converting it to GDP. This inactivation process is accelerated by GTPase-activating (GAP) proteins.
KRAS has emerged as a target of significant clinical interest, due to mutations in the KRAS protein that promote the pathogenesis of 20-30% of human cancers. Testing a patient for the presence of specific KRAS mutants serves as a highly predictive marker for success rates to various types of lung and colon cancer therapies. The development of inhibitors against KRAS G12C, G12D, and G12V holds a promising future for oncology.
We offer wild-type and mutant KRAS screening and profiling services to identify specific inhibitors. Our team of experts, using our in-house developed biochemical assay kits, can provide:
Screening for activity across your compound library
Determination of IC50
Project guidance and questions answered in a timely manner
Delivery of detailed results promptly and on time
If follow-up studies are required, we can provide the same active proteins as the ones used in our assays.
Fluorogenic Nucleotide Exchange Assays are homogeneous assays designed for the screening and profiling of KRAS antagonists/inhibitors. In this assay, KRAS is pre-loaded with fluorescent BODIPY-GDP. Adding GTP in the presence of EDTA displaces BODIPY-GDP. The fluorescence intensity decreases as the BODIPY-GDP is displaced by GTP. Several KRAS inhibitors lock KRAS in the (inactive) GDP-bound conformation and prevent GDP/GTP exchange. In this scenario, the fluorescence intensity increases with drug concentration as more BODIPY-GDP remains bound to KRAS.
AlphaLISA® Coupled Nucleotide Exchange Assays are designed for the screening and profiling of KRAS antagonists/inhibitors by monitoring the binding of an effector protein such as the Ras binding domain of Raf1, (RBD-cRaf) to active KRAS (G12C, in this example). First, a sample containing GDP-loaded KRAS(G12C) is incubated with SOS1 and GTP for the nucleotide exchange. Next, RBD-cRAF is added and incubated for the effector-RAS binding. Then, acceptor and donor beads are added and incubated for detection followed by reading the Alpha-counts.
Nucleotide Exchange AssaysKRAS Isoform B KRAS (G12C) KRAS (G12D) | Coupled Nucleotide Exchange AssaysKRAS (G12C) KRAS (G12D) KRAS (G12V) |
如果您需要了解更多關(guān)于我們的服務(wù)的信息,請(qǐng)聯(lián)系info。
請(qǐng)輸入賬號(hào)
請(qǐng)輸入密碼
請(qǐng)輸驗(yàn)證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé),化工儀器網(wǎng)對(duì)此不承擔(dān)任何保證責(zé)任。
溫馨提示:為規(guī)避購(gòu)買風(fēng)險(xiǎn),建議您在購(gòu)買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。